Literature DB >> 18000954

Monocyte-mediated T cell suppression by HIV-2 envelope proteins.

Rita Cavaleiro1, Gregory J Brunn, Adriana S Albuquerque, Rui M M Victorino, Jeffrey L Platt, Ana E Sousa.   

Abstract

HIV-2 is associated with an attenuated form of HIV disease. We investigate here the immunosuppressive effects of the HIV-2 envelope protein, gp105. We found that gp105 suppresses activation of T cells through a monocyte-mediated mechanism. Suppression of T cell activation by gp105 depends on contact between monocytes and T cells, but not on CD4+CD25+ T cells. The TLR4 pathway is likely involved, since gp105 activates TLR4 signaling and induces TNF-alpha production by monocytes. Immunosuppression is viewed as the main pathophysiologic consequence of infection by HIV. However, the main immunologic defect caused by HIV, depletion of T cells, requires T cell activation. Our findings are consistent with a new concept that HIV-2 envelope proteins act on monocytes to suppress T cell activation and that this property may contribute to the benign course of HIV-2. We hypothesize that the HIV-2 envelope immunosuppressive properties limit bursts of T cell activation, thus reducing viremia and contributing to the slow rate of disease progression that characterizes HIV-2 disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000954     DOI: 10.1002/eji.200737511

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.

Authors:  Helena Skar; Pedro Borrego; Timothy C Wallstrom; Mattias Mild; José Maria Marcelino; Helena Barroso; Nuno Taveira; Thomas Leitner; Jan Albert
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

Review 2.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

3.  Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes.

Authors:  Helena Nunes-Cabaço; Paula Matoso; Russell B Foxall; Rita Tendeiro; Ana R Pires; Tânia Carvalho; Ana I Pinheiro; Rui S Soares; Ana E Sousa
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

Review 4.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

5.  Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.

Authors:  Helena Barroso; Pedro Borrego; Inês Bártolo; José Maria Marcelino; Carlos Família; Alexandre Quintas; Nuno Taveira
Journal:  PLoS One       Date:  2011-01-20       Impact factor: 3.240

6.  Faster HIV-1 disease progression among Brazilian individuals recently infected with CXCR4-utilizing strains.

Authors:  Maria Cecilia Araripe Sucupira; Sabri Sanabani; Rodrigo M Cortes; Maria Teresa M Giret; Helena Tomiyama; Mariana M Sauer; Ester Cerdeira Sabino; Luiz Mario Janini; Esper Georges Kallas; Ricardo Sobhie Diaz
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

Review 7.  Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections.

Authors:  K K Vidya Vijayan; Krithika Priyadarshini Karthigeyan; Srikanth P Tripathi; Luke Elizabeth Hanna
Journal:  Front Immunol       Date:  2017-05-23       Impact factor: 7.561

8.  Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.

Authors:  Rita Cavaleiro; António P Baptista; Rui S Soares; Rita Tendeiro; Russell B Foxall; Perpétua Gomes; Rui M M Victorino; Ana E Sousa
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.